Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Royer

Showing results (41-50 of 107) with videos related to

Pageof 11
Sort By:
Frontiers in Immunology|December 26, 2022
Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life studyPierre-Edouard Debureaux, Stéphanie Harel, Nathalie Parquet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2005
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-AutogreffeJean-Paul Fermand, Sandrine Katsahian, Marine Divine, et al.
European Journal of Heart Failure|October 2, 2020
Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosisMartin Nicol, Antoine Deney, Olivier Lairez, et al.
American Journal of Hematology|October 4, 2016
A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)Marc Michel, Louis Terriou, Francoise Roudot-Thoraval, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 25, 2024
Prognostic value of CMR-derived extracellular volume in AL amyloidosis: a multicenter studyMartin Nicol, Cassiel Kitzinger, Mathilde Baudet, et al.
Hemasphere|July 31, 2024
Impact of second autologous stem-cell transplantation at relapsed multiple myeloma: A French multicentric real-life studyAxel André, Lydia Montes, Damien Roos-Weil, et al.
Blood Cancer Journal|January 12, 2021
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosisVikram J Premkumar, Suzanne Lentzsch, Samuel Pan, et al.
Journal of Clinical Immunology|June 25, 2020
Correction to: A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary ImmunodeficiencyHélène Coignard-Biehler, Nizar Mahlaoui, Benoit Pilmis, et al.
The New England Journal of Medicine|September 15, 2007
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosisArnaud Jaccard, Philippe Moreau, Veronique Leblond, et al.
Blood|February 17, 2012
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trialStephane Lepretre, Therese Aurran, Beatrice Mahé, et al.
Pageof 11

Showing results (41-50 of 107) with videos related to

Sort By:
Pageof 11
Frontiers in Immunology|December 26, 2022
Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life studyPierre-Edouard Debureaux, Stéphanie Harel, Nathalie Parquet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2005
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-AutogreffeJean-Paul Fermand, Sandrine Katsahian, Marine Divine, et al.
European Journal of Heart Failure|October 2, 2020
Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosisMartin Nicol, Antoine Deney, Olivier Lairez, et al.
American Journal of Hematology|October 4, 2016
A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)Marc Michel, Louis Terriou, Francoise Roudot-Thoraval, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 25, 2024
Prognostic value of CMR-derived extracellular volume in AL amyloidosis: a multicenter studyMartin Nicol, Cassiel Kitzinger, Mathilde Baudet, et al.
Hemasphere|July 31, 2024
Impact of second autologous stem-cell transplantation at relapsed multiple myeloma: A French multicentric real-life studyAxel André, Lydia Montes, Damien Roos-Weil, et al.
Blood Cancer Journal|January 12, 2021
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosisVikram J Premkumar, Suzanne Lentzsch, Samuel Pan, et al.
Journal of Clinical Immunology|June 25, 2020
Correction to: A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary ImmunodeficiencyHélène Coignard-Biehler, Nizar Mahlaoui, Benoit Pilmis, et al.
The New England Journal of Medicine|September 15, 2007
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosisArnaud Jaccard, Philippe Moreau, Veronique Leblond, et al.
Blood|February 17, 2012
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trialStephane Lepretre, Therese Aurran, Beatrice Mahé, et al.
Pageof 11